Reality Check on Rheumatoid Arthritis
Market access for rheumatoid arthritis (RA) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: About 73% of the covered lives under the commercial formularies are covered with utilization management restrictions
- Class Trends: With more biosimilars coming to market to compete against some of the older biologic-based drugs, an industry expert suggests that the RA market will see more competition
- Key Findings: How payers manage physicians' and patients' desires, treatment costs and efficacy expectations is amazingly complex and ever-changing
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.